Pembrolizumab (Pem) for advanced non-small cell lung cancer (aNSCLC): Efficacy and safety in everyday clinical practice.

Doran Ksienski,Elaine S. Wai,Nicole S. Croteau,Ashley T. Freeman,Leathia Fiorino,Angela Chan,G. Geller,Zia Poonja,E Brooks,Dave Fenton,Sarah Irons,Mary Lesperance

Pembrolizumab (Pem) for advanced non-small cell lung cancer (aNSCLC): Efficacy and safety in everyday clinical practice.

2019

Doran Ksienski
Elaine S. Wai
Nicole S. Croteau
Ashley T. Freeman
Leathia Fiorino
Angela Chan
G. Geller
Zia Poonja
E Brooks
Dave Fenton
Sarah Irons
Mary Lesperance

e20506Background: In clinical trials, Pem improves overall survival (OS) compared to chemotherapy in a subset of patients (pts) with aNSCLC. Immune related adverse events (irAE) have correlated wit...

Keywords:

Clinical Practice
Cell
Immune system
Lung cancer
Clinical trial
Pembrolizumab
Oncology
Pathology
Adverse effect
Internal medicine
Chemotherapy
Medicine
non small cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations